{"nctId":"NCT00225147","briefTitle":"Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema","startDateStruct":{"date":"2005-07"},"conditions":["Hereditary Angioedema","Angioneurotic Edema"],"count":77,"armGroups":[{"label":"100 IU/kg rhC1INH","type":"EXPERIMENTAL","interventionNames":["Drug: Recombinant Human C1 Inhibitor"]},{"label":"50 IU/kg rhC1INH","type":"EXPERIMENTAL","interventionNames":["Drug: Recombinant Human C1 Inhibitor"]},{"label":"Saline","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Recombinant Human C1 Inhibitor","otherNames":["\"rhC1INH\"","Ruconest","conestat alfa"]},{"name":"placebo","otherNames":["saline","physiological salt solution"]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Clear clinical and laboratory diagnosis of HAE\n* Plasma level of functional C1INH of less than 50% of normal\n* Acute abdominal, urogenital, peripheral, and/or oro-facial/pharyngeal/laryngeal HAE attack\n\nMain Exclusion Criteria:\n\n* Acquired angioedema\n* Pregnancy or breastfeeding\n* Treatment with any investigational drug within prior 30 days\n* Body weight \\>120 kg","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Beginning of Relief of Symptoms","description":"The time to beginning of relief of symptoms at the location that showed the first visual analogue scale (\"VAS\") score decrease of at least 20 mm from baseline score with persistence to the next timepoint, assessment timepoints were taken on pre-scheduled time-points after study drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours and 48 hours. Time to beginning of relief has been calculated as median time, by using the exact timepoints on which each assessment was performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"122","spread":null},{"groupId":"OG002","value":"258","spread":null},{"groupId":"OG003","value":"62.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Minimal Symptoms","description":"The time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale (\"VAS\") score. Symptoms were said to be minimal when the \"VAS\" score at all locations was below 20 mm. Assessment timepoints were: baseline, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours and 48 hours. Time to minimal symtoms has been calculated by using the exact timepoints on which each assessment was performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":null},{"groupId":"OG001","value":"246.5","spread":null},{"groupId":"OG002","value":"1101","spread":null},{"groupId":"OG003","value":"145","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["headache","vertigo","diarrhea","nausea","sinusitis"]}}}